首页> 外文OA文献 >Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab

【2h】

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab

机译：奥沙利铂联合或不联合西妥昔单抗治疗转移性结直肠癌患者的血浆可溶性尿激酶受体完整和裂解

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Tarpgaard, Line S; Christensen, Ib J; Høyer-Hansen, Gunilla; Lund, Ida K; Guren, Tormod K; Glimelius, Bengt; Sorbye, Halfdan; Tveit, Kjell M; Nielsen, Hans Jørgen; Moreira, José M A; Pfeiffer, Per; Brünner, Nils;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020 ,第007期
2. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab [J] . Tarpgaard Line S., Christensen Ib J., Hoyer-Hansen Gunilla, International Journal of Cancer =: Journal International du Cancer . 2015 ,第10期

机译：奥沙利铂联合或不联合西妥昔单抗治疗转移性结直肠癌患者血浆中可溶性尿激酶的完整和裂解
3. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin. [J] . Han HS, Chang HJ, Hong YS, Diseases of the Colon and Rectum . 2009 ,第6期

机译：西妥昔单抗联合以伊立替康和奥沙利铂难治的基于伊立替康的化疗治疗转移性结直肠癌患者的表皮生长因子受体表达差异。
4. Let-7 miRNA-binding site polymorphism in the KRAS 3 ′ UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/? cetuximab [J] . Janne B Kjersem, Tone Ikdahl, Tormod Guren, BMC Cancer . 2012 ,第1期

机译：KRAS 3'UTR中的let-7 miRNA结合位点多态性; 5-氟尿嘧啶和奥沙利铂+ /？治疗转移性结直肠癌患者的结直肠癌筛查人群患病率及其对临床结局的影响西妥昔单抗
5. Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells In Vitro and In Vivo [C] . Viktor Magdolen International Meeting on Molecular Staging on Cancer . 2003

机译：抑制肿瘤相关的尿激酶型纤溶酶原激活系统：高水平合成在体外和体内卵巢癌细胞中可溶性尿激酶受体的影响
6. A Modeling-Based Evaluation of the Evidential Basis for and Cost Effectiveness of Intensive Post-Diagnosis Extra-Colonic Surveillance of Non-Metastatic Colorectal Cancer Patients [D] . Popp, Jonah. 2018

机译：非转移性结直肠癌患者强化诊断后大肠结肠镜检查的证据基础和成本效益的基于模型的评估
7. Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study [O] . Line S. Tarpgaard, Tormod K. Guren, Bengt Glimelius, 2010

机译：一线以奥沙利铂为基础的方案联合西妥昔单抗治疗或非西妥昔单抗治疗转移性大肠癌患者的血浆YKL-40：NORDIC VII研究的结果
8. Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab : RESULTS from the NORDIC VII Study [O] . Tarpgaard, Line S., Guren, Tormod K., Glimelius, Bengt, 2014

机译：一线以奥沙利铂为基础的方案联合西妥昔单抗治疗或非西妥昔单抗治疗转移性大肠癌患者的血浆YKL-40：NORDIC VII研究的结果

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab

著录项

相似文献

相关主题

期刊订阅